Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Eric Bjerkholt Sells 1,421 Shares

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 1,421 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $93.33, for a total transaction of $132,621.93. Following the transaction, the chief financial officer directly owned 42,127 shares in the company, valued at $3,931,712.91. This represents a 3.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Mirum Pharmaceuticals Price Performance

Shares of MIRM traded down $1.74 during mid-day trading on Friday, reaching $94.29. The stock had a trading volume of 802,708 shares, compared to its average volume of 890,067. The business has a fifty day moving average of $76.87 and a 200 day moving average of $70.34. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The firm has a market cap of $4.85 billion, a price-to-earnings ratio of -109.64 and a beta of 0.48. Mirum Pharmaceuticals, Inc. has a 12 month low of $36.88 and a 12 month high of $96.84.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.15. The company had revenue of $133.01 million for the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. Mirum Pharmaceuticals’s revenue for the quarter was up 47.1% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.30) EPS. Equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Hedge Funds Weigh In On Mirum Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. CWM LLC grew its stake in shares of Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after buying an additional 161 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Mirum Pharmaceuticals by 0.4% in the 2nd quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock valued at $2,189,000 after acquiring an additional 176 shares during the last quarter. MCF Advisors LLC grew its position in Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock worth $31,000 after acquiring an additional 185 shares in the last quarter. Teacher Retirement System of Texas increased its stake in Mirum Pharmaceuticals by 2.2% during the second quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock worth $504,000 after acquiring an additional 215 shares during the last quarter. Finally, Palumbo Wealth Management LLC increased its stake in Mirum Pharmaceuticals by 4.2% during the second quarter. Palumbo Wealth Management LLC now owns 5,604 shares of the company’s stock worth $285,000 after acquiring an additional 228 shares during the last quarter.

Analyst Ratings Changes

A number of research firms have recently weighed in on MIRM. Robert W. Baird upped their price objective on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research note on Monday, December 8th. Citizens Jmp upped their price target on Mirum Pharmaceuticals from $95.00 to $140.00 and gave the stock a “market outperform” rating in a research note on Friday, December 19th. Stifel Nicolaus increased their price objective on shares of Mirum Pharmaceuticals from $92.00 to $98.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. Finally, JMP Securities set a $95.00 target price on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $102.58.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.